ASH 2024 | 10-year update of mini–hyper-CVAD and Ino ± Blina in older patients with newly diagnosed Ph- B-ALL
Jayastu Senapati, MBBS, The University of Texas MD Anderson Cancer Center, Houston, TX, presents the 10-year update of a clinical trial (NCT01371630) testing the combination of inotuzumab ozogamicin (InO) and mini-hyper-CVAD with or without blinatumomab (Blina) in older patients (≥60 yrs) with Philadelphia negative (Ph-) B-cell acute lymphoblastic leukemia (B-ALL). Dr Senapati outlines that this combination therapy elicited encouraging response rates in a patient population with historically dismal outcomes. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
